Talking Medicines creates AI tool for patient experiences

Drug-GPT, which is available on Talking Medicine’s PatientMetRx 2.0 platform, uses curated social data to help uncover patient insights to inform healthcare advertising.

In addition, Drug-GPT provides natural language responses and summaries, with subscribers able to answer questions on how patients experience medication and treatments compared with the views of healthcare professionals.

The company licenses the GPT models from Microsoft to make sure of a closed ecosystem around Drug-GPT using its own curated social data of patients and healthcare practitioners.

The PatientMetRx 2.0 platform has also added other new features, such as a natural language search function and more ability to gauge the views of healthcare professionals.

Jo Halliday, chief executive and co-founder at Talking Medicines, said: “We are really excited by the potential of Drug-GPT to transform the way that healthcare advertising agencies analyse insights on complex patient and healthcare professional social data.”